Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

BTG Bidder Boston Scientific Sells Embolic Microsphere Business

(Alliance News) - BTG PLC on Thursday said Boston Scientific Corp has agreed to sell an existing ...

Alliance News 2 July, 2019 | 10:07AM
Email Form

(Alliance News) - BTG PLC on Thursday said Boston Scientific Corp has agreed to sell an existing business to Varian Medical Systems Inc.

The deal is subject to the GBP3.3 billion acquisition of FTSE 250-listed pharmaceutical firm BTG by Boston Scientific subsidiary Bravo Bidco Ltd at 840 pence per share. The BTG acquisition has been cleared in Germany.

The "drug-eluting and bland embolic microsphere business", which includes Oncozene, Embozene, and Embozone Tandem, will be sold for an undisclosed sum to Varian. The embolic microsphere business concerns products intended to restrict blood flow to hypervascular tumours and prostatic arteries.

Shares in BTG were up 0.3% at 837.25 pence in London on Tuesday. The former British Technology Group listed on the London Stock Exchange in 1995.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
BTG PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites